Article
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
Urologic oncology - 1 Mar 2022
Mertens Laura S, Claps Francesco, Mayr Roman, Bostrom Peter J, Shariat Shahrokh F, Zwarthoff Ellen C, Boormans Joost L, Abas Cheno, van Leenders Geert J L H, Götz Stefanie, Hippe Katrin, Bertz Simone, Neuzillet Yann, Sanders Joyce, Broeks Annegien, Peters Dennis, van der Heijden Michiel S, Jewett Michael A S, Stöhr Robert, Zlotta Alexandre R, Eckstein Markus, Soorojebally Yanish, van der Schoot Deric K E, Wullich Bernd, Burger Maximilian, Otto Wolfgang, Radvanyi François, Sirab Nanour, Pouessel Damien, van der Kwast Theo H, Hartmann Arndt, Lotan Yair, Allory Yves, Zuiverloon Tahlita C M, van Rhijn Bas W G
Abstract excerpt
OBJECTIVES: To determine the association between the FGFR3 mutation status and immuno-histochemistry (IHC) markers (p53 and Ki-67) in invasive bladder cancer (BC), and to analyze their prognostic value in a multicenter, multi-laboratory radical cystectomy (RC) cohort. PATIENTS AND METHODS: We included 1058 cN0M0, chemotherapy-naive BC patients who underwent RC with pelvic lymph-node dissection at 8 hospitals. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.